Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0002-1908-3307

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 110 papers. Top paper: “10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial”.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30210-6

N/A

6.4DataRank · unranked

334 citations

Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver +34 more

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

Nature(2023)10.1038/s41586-023-05812-3

N/A

5.2DataRank · unranked

480 citations

Ibrahim Aldoss, John F. Dipersio, Branko Cuglievan, Richard M. Stone, Martha Arellano +19 more

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

The Lancet Haematology(2021)10.1016/s2352-3026(21)00192-7

N/A

5.0DataRank · unranked

178 citations

Patrick K. Reville, Gautam Borthakur, Musa Yılmaz, Steven M. Kornblau, Yesid Alvarado +13 more

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Nature Medicine(2023)10.1038/s41591-022-02103-8

N/A

4.3DataRank · unranked

388 citations

Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric‐Bernstam +44 more

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

The Lancet Oncology(2021)10.1016/s1470-2045(21)00494-0

N/A

4.0DataRank · unranked

193 citations

Andre C. Schuh, Eytan M. Stein, Pau Montesinos, Andrew H. Wei, Stéphane de Botton +12 more

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax

Cancer(2021)10.1002/cncr.33689

N/A

3.9DataRank · unranked

158 citations

Abhishek Maiti, Sanam Loghavi, Rasoul Pourebrahim, Tapan M. Kadia, Caitlin R. Rausch +14 more

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Blood Advances(2021)10.1182/bloodadvances.2020003717

N/A

3.2DataRank · unranked

82 citations

Courtney D. DiNardo, Sa A. Wang, Jeffrey L. Jorgensen, Tapan M. Kadia, Naval Daver +28 more

Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study

Clinical Infectious Diseases(2020)10.1093/cid/ciaa358

N/A

3.1DataRank · unranked

77 citations

David McCue, Sebastian Wurster, Nathan P. Wiederhold, Marina Konopleva, Tapan M. Kadia +18 more

Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia

Blood Advances(2020)10.1182/bloodadvances.2019000767

N/A

2.9DataRank · unranked

56 citations

Wendy Stock, Amer M. Zeidan, Ehab Atallah, James McCloskey, Leonard T. Heffner +11 more

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML

Journal of Clinical Oncology(2024)10.1200/jco.23.01911

N/A

2.7DataRank · unranked

152 citations

Naval Daver, Courtney D. DiNardo, Tapan M. Kadia, Lewis Nasr, Walid Macaron +19 more

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia

Blood(2021)10.1182/blood.2021013290

N/A

2.6DataRank · unranked

87 citations

Pinaki P. Banerjee, Denái R. Milton, Xianli Jiang, Christina Ganesh, Sajad Khazal +24 more

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

Blood Cancer Journal(2022)10.1038/s41408-021-00604-2

N/A

2.5DataRank · unranked

95 citations

Koichi Takahashi, Naval Daver, Abhishek Maiti, Gautam Borthakur, Sanam Loghavi +14 more

Decitabine and venetoclax for IDH1/2‐mutated acute myeloid leukemia

American Journal of Hematology(2021)10.1002/ajh.26122

N/A

1.4DataRank · unranked

25 citations

Abhishek Maiti, Courtney D. DiNardo, Sanam Loghavi, Naval Daver, Tapan M. Kadia +11 more

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

Journal of Hematology & Oncology(2023)10.1186/s13045-023-01476-8

N/A

1.3DataRank · unranked

51 citations

Muharrem Müftüoğlu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban‐Bravo +22 more

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Blood(2020)10.1182/blood.2019003988

N/A

0.969DataRank · unranked

638 citations

Ing Soo Tiong, Anna Quaglieri, Sarah MacRaild, Sanam Loghavi, Fiona C. Brown +24 more

Impact of Philadelphia chromosome‐like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study

American Journal of Hematology(2021)10.1002/ajh.26281

N/A

0.952DataRank · unranked

32 citations

Keyur P. Patel, Nitin Jain, Dzifa Y. Duose, Rajyalakshmi Luthra, Nicholas J. Short +8 more

Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine

Leukemia & lymphoma/Leukemia and lymphoma(2021)10.1080/10428194.2021.1973675

N/A

0.308DataRank · unranked

5 citations

Abhishek Maiti, Courtney D. DiNardo, Wei Qiao, Jing Ning, Sanam Loghavi +13 more

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial

Cancer(2025)10.1002/cncr.35840

N/A

0.104DataRank · unranked

1 citations

Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Elias Jabbour +13 more

Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7512

N/A

0DataRank · unranked

10 citations

Abhishek Maiti, Farhad Ravandi, Marina Konopleva, Yesid Alvarado, Tapan M. Kadia +14 more

Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7519

N/A

0DataRank · unranked

8 citations

Courtney D. DiNardo, Naveen Pemmaraju, Tapan M. Kadia, Caitlin R. Rausch, Kiran Naqvi +15 more

Only SF3B1 Mutation involving K700E (And Not Other Codons), Independently Predicts Overall Survival in Myelodysplastic Syndromes

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.09.04.283598

N/A

0DataRank · unranked

0 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Elias Jabbour, Carlos E. Bueso‐Ramos, Yue Wei +14 more

Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980–2017

American Journal of Hematology(2021)10.1002/ajh.26156

N/A

0DataRank · unranked

128 citations

Elias Jabbour, Nicholas J. Short, Nitin Jain, Farhad Ravandi, Ching‐Hon Pui +2 more

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Blood Cancer Journal(2021)10.1038/s41408-021-00410-w

N/A

0DataRank · unranked

126 citations

Courtney D. DiNardo, Naval Daver, Caitlin R. Rausch, Farhad Ravandi, Tapan M. Kadia +20 more

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

Nature Communications(2021)10.1038/s41467-021-22874-x

N/A

0DataRank · unranked

117 citations

Kiyomi Morita, Courtney D. DiNardo, Ken Furudate, Tomoyuki Tanaka, Yuanqing Yan +21 more

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements

Blood Cancer Journal(2021)10.1038/s41408-021-00557-6

N/A

0DataRank · unranked

99 citations

Jabra Zarka, Koji Sasaki, Wei Qiao, Daewoo Pak, Jing Ning +16 more

Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia

Blood(2021)10.1182/blood.2020010603

N/A

0DataRank · unranked

80 citations

Arda Durmaz, Carmelo Gurnari, Ashwin Kishtagari, Manja Meggendorfer, Cassandra M Kerr +19 more

The cure of leukemia through the optimist's prism

Cancer(2021)10.1002/cncr.33933

N/A

0DataRank · unranked

67 citations

Nitin Jain, Guillermo Garcia‐Manero, Mary Alma Welch, Farhad Ravandi, William G. Wierda +2 more

Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia

American Journal of Hematology(2021)10.1002/ajh.26238

N/A

0DataRank · unranked

55 citations

Abhishek Maiti, Farhad Ravandi, Marina Konopleva, Naval Daver, Tapan M. Kadia +8 more

Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis

Cancer(2021)10.1002/cncr.33814

N/A

0DataRank · unranked

51 citations

Courtney D. DiNardo, Wei Qiao, Tapan M. Kadia, Elias Jabbour, Caitlin R. Rausch +18 more

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

Blood Cancer Journal(2021)10.1038/s41408-021-00453-z

N/A

0DataRank · unranked

45 citations

Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Courtney D. DiNardo, Naval Daver +12 more

Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia

Blood(2021)10.1182/blood.2020010483

N/A

0DataRank · unranked

43 citations

Kiyomi Morita, Sanam Loghavi, Feng Wang, Ken Furudate, Yuya Sasaki +19 more

Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications

Frontiers in Immunology(2021)10.3389/fimmu.2020.590494

N/A

0DataRank · unranked

43 citations

Ajay Sheshadri, Vickie R. Shannon, Dimitrios P. Kontoyiannis, Hagop M. Kantarjian, Guillermo Garcia‐Manero +20 more

Impact of frontline treatment approach on outcomes of myeloid blast phase CML

Journal of Hematology & Oncology(2021)10.1186/s13045-021-01106-1

N/A

0DataRank · unranked

37 citations

Elias Jabbour, Ghayas C. Issa, Koji Sasaki, Farhad Ravandi, Abhishek Maiti +11 more

Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes

Cancer(2021)10.1002/cncr.33745

N/A

0DataRank · unranked

32 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Faezeh Darbaniyan, Elias Jabbour, Carlos E. Bueso‐Ramos +13 more

Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

Leukemia(2021)10.1038/s41375-021-01240-2

N/A

0DataRank · unranked

31 citations

Danielle Hammond, Courtney D. DiNardo, Marina Konopleva, Gautam Borthakur, Nicholas J. Short +15 more

Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations

Blood(2021)10.1182/blood.2021012315

N/A

0DataRank · unranked

24 citations

Ekaterina Kim, William G. Wierda, Alessandra Ferrajoli, Nitin Jain, Philip A. Thompson +4 more

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis

Blood Cancer Journal(2021)10.1038/s41408-021-00446-y

N/A

0DataRank · unranked

10 citations

Guillermo Montalban‐Bravo, Panagiotis Katsonis, Koji Sasaki, Caleb A. Class, Elias Jabbour +26 more

Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission

Cancer(2021)10.1002/cncr.33409

N/A

0DataRank · unranked

10 citations

Hagop M. Kantarjian, Farhad Ravandi, Naval Daver, Xuemei Wang, Elias Jabbour +16 more

Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Nature Communications(2021)10.1038/s41467-021-23280-z

N/A

0DataRank · unranked

7 citations

Feng Wang, Katharina Jahn, Tianyuan Hu, Tomoyuki Tanaka, Yuya Sasaki +28 more

Contemporary outcomes for adults with AML requiring ICU admission.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7025

N/A

0DataRank · unranked

4 citations

Koji Sasaki, Alexis Geppner, Fadi Haddad, Shehab Mohamed, Daniel Rivera +15 more

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms

Blood(2022)10.1182/blood.2021014956

N/A

0DataRank · unranked

140 citations

Veronica Guerra, James A. Kennedy, Yuanqing Yan, Joanne I. Hsu, Feng Wang +20 more

The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis

Blood(2022)10.1182/blood.2022016194

N/A

0DataRank · unranked

88 citations

Michael Slade, Hagop M. Kantarjian, Julio Alvarenga, Ibrahim Aldoss, Kahee A. Mohammed +16 more

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Blood Advances(2022)10.1182/bloodadvances.2022008316

N/A

0DataRank · unranked

56 citations

Aram Bidikian, Sangeetha Venugopal, Marina Konopleva, Courtney D. DiNardo, Tapan M. Kadia +20 more

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia

Blood Cancer Journal(2022)10.1038/s41408-022-00742-1

N/A

0DataRank · unranked

51 citations

Hagop M. Kantarjian, Elias Jabbour, Nicholas J. Short, Keyur P. Patel, Farhad Ravandi +3 more

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells

Nature Communications(2022)10.1038/s41467-022-29669-8

N/A

0DataRank · unranked

43 citations

Agnès Gouble, Kathryn L. Black, Anna Skwarska, Ammar S. Naqvi, Deanne Taylor +28 more

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Blood(2022)10.1182/blood.2022015832

N/A

0DataRank · unranked

36 citations

Pierre Fenaux, Marco Gobbi, Jiřı́ Mayer, Gail J. Roboz, Jürgen Krauter +21 more

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

Journal of Hematology & Oncology(2022)10.1186/s13045-022-01229-z

N/A

0DataRank · unranked

32 citations

Sangeetha Venugopal, Wei Qiao, Tapan M. Kadia, Farhad Ravandi, Walid Macaron +18 more

Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL

Leukemia(2022)10.1038/s41375-022-01516-1

N/A

0DataRank · unranked

32 citations

Ya‐Ling Yang, Seemana Bhattacharya, Priyanka Sharma, Huaxian Ma, Hong Mu +11 more

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

American Journal of Hematology(2022)10.1002/ajh.26451

N/A

0DataRank · unranked

23 citations

Koji Sasaki, Hagop M. Kantarjian, Naval Daver, Musa Yılmaz, Courtney D. DiNardo +13 more

TP53‐altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity

Cancer(2022)10.1002/cncr.34535

N/A

0DataRank · unranked

17 citations

Naval Daver, Jessica K. Altman, Robert P. Hasserjian, Hagop M. Kantarjian, Uwe Platzbecker +5 more

TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis

American Journal of Hematology(2022)10.1002/ajh.26595

N/A

0DataRank · unranked

14 citations

Raamis Khwaja, Rashmi Kanagal‐Shamanna, Guilin Tang, Jan A. Burger, Philip A. Thompson +10 more

Targeting Oxidative Phosphorylation with a Mitochondrial Complex I Inhibitor is limited by Mechanism-based Toxicity

Research Square(2022)10.21203/rs.3.rs-1506700/v1

N/A

0DataRank · unranked

5 citations

Timothy A. Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka +43 more

Characteristics of patients with myelofibrosis on ruxolitinib for three or more years.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e19082

N/A

0DataRank · unranked

0 citations

Prithviraj Bose, Naveen Pemmaraju, Helen T. Chifotides, Lingsha Zhou, Zeev Estrov +3 more

Phase II study of lower-intensity frontline therapy for newly diagnosed patients with AML who are unfit or otherwise not eligible for frontline clinical trials.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e19028

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Naveen Pemmaraju, Guillermo Montalban‐Bravo, Kelly S. Chien, Naval Daver +12 more

Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants

American Journal of Hematology(2023)10.1002/ajh.27070

N/A

0DataRank · unranked

47 citations

Sanam Loghavi, Yoheved Gerstein, Alexandre Bazinet, Koji Sasaki, Kelly S. Chien +19 more

Outcome of Philadelphia chromosome‐positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019

Cancer(2023)10.1002/cncr.35038

N/A

0DataRank · unranked

32 citations

Fadi Haddad, Nicholas J. Short, Nitin Jain, Ghayas C. Issa, Elias Jabbour +2 more

Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia

Clinical Lymphoma Myeloma & Leukemia(2023)10.1016/j.clml.2023.12.016

N/A

0DataRank · unranked

23 citations

Elias Jabbour, Trevor Jamison, Shilpa Paul, Branko Cuglievan, David McCall +11 more

Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

Molecular Cancer Research(2023)10.1158/1541-7786.mcr-22-0343

N/A

0DataRank · unranked

16 citations

Sujan Piya, Huaxian Ma, Priyanka Sharma, Qi Zhang, Natalia Baran +10 more

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Blood Advances(2023)10.1182/bloodadvances.2022009632

N/A

0DataRank · unranked

24 citations

Faustine Ong, Farhad Ravandi, Graciela M. Nogueras‐González, Tapan M. Kadia, Naval Daver +15 more

Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation

Cancer(2023)10.1002/cncr.34728

N/A

0DataRank · unranked

20 citations

Hagop M. Kantarjian, Nicholas J. Short, Wei Qiao, Jing Ning, Branko Cuglievan +12 more

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era

American Journal of Hematology(2023)10.1002/ajh.27037

N/A

0DataRank · unranked

20 citations

Koji Sasaki, Aram Bidikian, Ghayas C. Issa, Tapan M. Kadia, Nitin Jain +11 more

Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation

American Journal of Hematology(2023)10.1002/ajh.26997

N/A

0DataRank · unranked

18 citations

Hagop M. Kantarjian, Naszrin Arani, Uday Popat, Álex Bataller, Koji Sasaki +19 more

Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression

Leukemia(2023)10.1038/s41375-023-02108-3

N/A

0DataRank · unranked

11 citations

Warren Fiskus, Tapan M. Kadia, Christopher P. Mill, Koji Sasaki, Naval Daver +13 more

Association between bariatric surgery and outcomes in chronic myeloid leukemia

Cancer(2023)10.1002/cncr.34725

N/A

0DataRank · unranked

11 citations

Hagop M. Kantarjian, Aram Bidikian, Elias Jabbour, Nicholas J. Short, Jing Ning +10 more

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1

Leukemia(2023)10.1038/s41375-023-01882-4

N/A

0DataRank · unranked

10 citations

Warren Fiskus, Kaberi Das, John A. Davis, Christine Birdwell, Tapan M. Kadia +11 more

Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept

Frontiers in Immunology(2023)10.3389/fimmu.2023.1249511

N/A

0DataRank · unranked

9 citations

Naval Daver, Myrna C. B. Godoy, Girish S. Shroff, Carol C. Wu, Luis F. Torre-Sada +19 more

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood(2023)10.1182/blood-2023-188084

N/A

0DataRank · unranked

1 citations

Philip A. Thompson, Akhil Jain, Jan A. Burger, Alessandra Ferrajoli, Jayastu Senapati +27 more

Single-Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms

Blood(2023)10.1182/blood-2023-190400

N/A

0DataRank · unranked

1 citations

Zongrui Li, Abhishek Maiti, Tomoyuki Tanaka, Hidetaka Uryu, Ken Furudate +21 more

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

medRxiv(2023)10.1101/2023.12.06.23299616

N/A

0DataRank · unranked

1 citations

Nicholas J. Short, Hagop M. Kantarjian, Ti‐Cheng Chang, Pankaj S. Ghate, Chunxu Qu +17 more

Bayesian Learning of Personalized Longitudinal Biomarker Trajectory

Annals of Data Science(2023)10.1007/s40745-023-00486-0

N/A

0DataRank · unranked

0 citations

Xuelin Huang, Chan Shen, Hagop M. Kantarjian, Shouhao Zhou

Validation of the Prognostic Risk Signatures for Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Blood(2023)10.1182/blood-2023-182841

N/A

0DataRank · unranked

0 citations

Alexandre Bazinet, Courtney D. DiNardo, Gautam Borthakur, Nicholas J. Short, Elias Jabbour +12 more

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Blood(2023)10.1182/blood-2023-188051

N/A

0DataRank · unranked

0 citations

Meixian Huang, Sharon Bledsoe, Naveen Pemmaraju, Tapan M. Kadia, Prithviraj Bose +10 more

Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions

Journal of Hematology & Oncology(2024)10.1186/s13045-024-01552-7

N/A

0DataRank · unranked

19 citations

Elias Jabbour, Nitin B. Jain, Hagop M. Kantarjian, Nicholas J. Short

Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study

Haematologica(2024)10.3324/haematol.2023.284078

N/A

0DataRank · unranked

15 citations

Lucia Masárová, Naveen Pemmaraju, Sharon Bledsoe, Naval Daver, Elias Jabbour +19 more

Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101585

N/A

0DataRank · unranked

14 citations

Natthakan Thongon, Juan José Rodríguez‐Sevilla, Feiyang Ma, Irene Gañán‐Gómez, Hui Yang +16 more

Safety and long‐term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single‐center phase 1,2 trial

American Journal of Hematology(2024)10.1002/ajh.27254

N/A

0DataRank · unranked

5 citations

Kamal Alzahrani, Hagop M. Kantarjian, Denái R. Milton, Alison Gulbis, Koji Sasaki +18 more

Artificial Intelligence Assessment of Chest Radiographs for COVID-19

Clinical Lymphoma Myeloma & Leukemia(2024)10.1016/j.clml.2024.11.013

N/A

0DataRank · unranked

2 citations

Guillermo Garcia‐Manero, Masayuki Nigo, Elias Jabbour, Farhad Ravandi, William G. Wierda +14 more

Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Blood(2024)10.1182/blood-2024-209558

N/A

0DataRank · unranked

2 citations

Wei‐Ying Jen, Courtney D. DiNardo, Kelly S. Chien, Danielle Hammond, Yesid Alvarado Valero +12 more

Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia

Blood(2024)10.1182/blood-2024-208890

N/A

0DataRank · unranked

1 citations

Kelly S. Chien, Sanam Loghavi, Rashmi Kanagal‐Shamanna, Anuya Natu, Mark E. Gurney +22 more

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Blood(2024)10.1182/blood-2024-203938

N/A

0DataRank · unranked

1 citations

Hagop M. Kantarjian, Musa Yılmaz, Naval Daver, Gautam Borthakur, Courtney D. DiNardo +15 more

Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods

Blood(2024)10.1182/blood-2024-210779

N/A

0DataRank · unranked

0 citations

Hussein A. Abbas, Guillermo Garcia‐Manero, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo +19 more

Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring

American Journal of Hematology(2025)10.1002/ajh.27708

N/A

0DataRank · unranked

48 citations

Elias Jabbour, Hagop M. Kantarjian

Management of chronic myeloid leukemia in 2025

Cancer(2025)10.1002/cncr.35953

N/A

0DataRank · unranked

37 citations

Massimo Breccia, Fadi Haddad, Rüdiger Hehlmann, Ghayas C. Issa, Hemant Malhotra +5 more

Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0229

N/A

0DataRank · unranked

15 citations

Jayastu Senapati, Hagop M. Kantarjian, Bofei Wang, Patrick K. Reville, Sanam Loghavi +21 more

Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation

Nature Genetics(2025)10.1038/s41588-025-02235-w

N/A

0DataRank · unranked

11 citations

Koichi Saeki, Hiroshi Haeno, Chiraag D. Kapadia, Ken Furudate, Jyoti Nangalia +39 more

Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies

American Journal of Hematology(2025)10.1002/ajh.70046

N/A

0DataRank · unranked

4 citations

Sanam Loghavi, Alexandre Bazinet, Álex Bataller, Ian Bouligny, Naval Daver +15 more

Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia

Blood Advances(2025)10.1182/bloodadvances.2025016565

N/A

0DataRank · unranked

3 citations

Hagop M. Kantarjian, Nitin B. Jain, Tapan M. Kadia, Jayastu Senapati, Fadi Haddad +12 more

MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia

British Journal of Haematology(2025)10.1111/bjh.70171

N/A

0DataRank · unranked

3 citations

Guojun Tang, Eitan Kugler, Jennifer Croden, Koji Sasaki, Alexandre Bazinet +20 more

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial

Blood Cancer Journal(2025)10.1038/s41408-025-01265-1

N/A

0DataRank · unranked

1 citations

Courtney D. DiNardo, Abhishek Maiti, Naveen Pemmaraju, Maro Ohanian, Naval Daver +19 more

SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Can Be Treated with Chemotherapy-Free Regimens without Transplant

Clinical Lymphoma Myeloma & Leukemia(2025)10.1016/j.clml.2025.06.019

N/A

0DataRank · unranked

0 citations

Hagop M. Kantarjian, Jayastu Senapati, Nitin Jain, Nicholas J. Short, Elias Jabbour +1 more

Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With KMT2A Rearrangements Treated With Immunotherapy‐Based Regimens

American Journal of Hematology(2025)10.1002/ajh.70048

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Nicholas J. Short, Nitin Jain, Ghayas C. Issa, Himachandana Atluri +9 more

SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia—How to Define the Treatment Value?

Clinical Lymphoma Myeloma & Leukemia(2025)10.1016/j.clml.2025.10.001

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Massimo Breccia, Rüdiger Hehlmann, Hemant Malhotra, Franck E. Nicolini +3 more

1250MO Outcomes of patients with chronic myeloid leukemia receiving second-line therapy

Annals of Oncology(2025)10.1016/j.annonc.2025.08.1884

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Sara Dellasala, G. Issa, Tapan Kadia, J. Senapati +10 more

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Blood Advances(2020)10.1182/bloodadvances.2020003120

N/A

0DataRank · unranked

182 citations

Guillermo Montalban‐Bravo, Hyunsoo Hwang, Jing Ning, Miguel Franquiz, Rashmi Kanagal‐Shamanna +12 more

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Haematologica(2020)10.3324/haematol.2020.252569

N/A

0DataRank · unranked

174 citations

Caitlin R. Rausch, Jörge E. Cortes, Naveen Pemmaraju, Naval Daver, Farhad Ravandi +30 more

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Nature Communications(2020)10.1038/s41467-020-19119-8

N/A

0DataRank · unranked

391 citations

Feng Wang, Katharina Jahn, Tianyuan Hu, Tomoyuki Tanaka, Yuya Sasaki +28 more

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia

JAMA Oncology(2020)10.1001/jamaoncol.2020.4600

N/A

0DataRank · unranked

373 citations

Shouhao Zhou, Chenqi Fu, Donald A. Berry, Roland B. Walter, Sylvie Freeman +8 more

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Blood Advances(2020)10.1182/bloodadvances.2019001101

N/A

0DataRank · unranked

133 citations

Rashmi Kanagal‐Shamanna, Christopher B. Benton, Caleb A. Class, Kelly S. Chien, Koji Sasaki +17 more

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

American Journal of Hematology(2020)10.1002/ajh.26061

N/A

0DataRank · unranked

103 citations

Wei Qiao, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Elias Jabbour +26 more

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Leukemia(2020)10.1038/s41375-020-0778-0

N/A

0DataRank · unranked

52 citations

Srđan Verstovšek, Jörge E. Cortes, Susan Tse, Yvonne Gasior, Nitin Jain +19 more

Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia

Cancer(2020)10.1002/cncr.32623

N/A

0DataRank · unranked

21 citations

Jörge E. Cortes, Keyur P. Patel, Susan O’Brien, Graciela M. Nogueras‐González, Marina Konopleva +11 more

Germline DNMT3A mutation in familial acute myeloid leukaemia

Epigenetics(2020)10.1080/15592294.2020.1809871

N/A

0DataRank · unranked

10 citations

Hannah C. Beird, Marcos R. Estecio, Swanand Hardikar, Koichi Takahashi, Sarah A. Bannon +12 more

Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia

Blood Advances(2020)10.1182/bloodadvances.2019001156

N/A

0DataRank · unranked

43 citations

Keyur P. Patel, Maher Albitar, Miguel Franquiz, Rajyalakshmi Luthra, Rashmi Kanagal‐Shamanna +15 more

Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL

Blood Cancer Journal(2020)10.1038/s41408-020-0329-y

N/A

0DataRank · unranked

36 citations

Hagop M. Kantarjian, Rashmi Kanagal‐Shamanna, Koji Sasaki, Farhad Ravandi, Jörge E. Cortes +15 more

Long‐term results of frontline dasatinib in chronic myeloid leukemia

Cancer(2020)10.1002/cncr.32627

N/A

0DataRank · unranked

34 citations

Jörge E. Cortes, Keyur P. Patel, Lucia Masárová, Gautam Borthakur, Farhad Ravandi +14 more

Long‐term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

Cancer(2020)10.1002/cncr.33298

N/A

0DataRank · unranked

32 citations

Nicola Gökbuget, Gerhard Zugmaier, Anthony S. Stein, Hervé Dombret, Yuqi Chen +5 more

Clinical value of event-free survival in acute myeloid leukemia

Blood Advances(2020)10.1182/bloodadvances.2019001150

N/A

0DataRank · unranked

7 citations

Hagop M. Kantarjian, Vinita Popat, Gautam Borthakur, Guillermo Garcia‐Manero, Marina Konopleva +16 more

Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3)

American Journal of Hematology(2020)10.1002/ajh.25991

N/A

0DataRank · unranked

6 citations

Guillermo Montalban‐Bravo, Rashmi Kanagal‐Shamanna, Elias Jabbour, Farhad Ravandi, Tapan M. Kadia +13 more

Clonal Evolution of Acute Myeloid Leukemia Revealed by High-Throughput Single-Cell Genomics

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.02.07.925743

N/A

0DataRank · unranked

67 citations

Feng Wang, Katharina Jahn, Jack Kuipers, Yuanqing Yan, Jairo Matthews +22 more

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.10.27.357111

N/A

0DataRank · unranked

20 citations

Kiyomi Morita, Courtney D. DiNardo, Ken Furudate, Tomoyuki Tanaka, Yuanqing Yan +21 more